Antares Pharma to Present at the Jefferies 2019 London Healthcare Conference
November 13 2019 - 7:00AM
Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F.
Apple, President and Chief Executive Officer, will present at the
Jefferies 2019 London Healthcare Conference on Wednesday November
20, 2019, at 11:20 am (GMT) / 6:20 am (EST) in London, UK.
A live webcast of the presentation will be
available under the “For Investors” section of the Antares website,
www.antarespharma.com.
About Antares Pharma
Antares Pharma, Inc. is a combination drug
device company focused primarily on the development and
commercialization of self-administered parenteral pharmaceutical
products using advanced drug delivery auto injector
technology. The Company has a portfolio of proprietary and
partnered commercial products with several product candidates in
various stages of development, as well as significant strategic
alliances with industry leading pharmaceutical companies including
Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals,
Inc. and Pfizer Inc. (Pfizer). Antares Pharma’s proprietary
products include XYOSTED® (testosterone enanthate) injection,
OTREXUP® (methotrexate) injection for subcutaneous use and
Sumatriptan Injection USP, which is distributed by Teva.
SAFE HARBOR STATEMENT UNDER THE PRIVATE
SECURITIES LITIGATION REFORM ACT OF 1995
This press release contains
forward-looking statements within the meaning of the safe harbor
provisions of the Private Securities Litigation Reform Act of
1995. Forward-looking statements are subject to certain risks
and uncertainties that can cause actual results to differ
materially from those described. Factors that may cause such
differences include, but are not limited to: market acceptance,
adequate reimbursement coverage and commercial success of XYOSTED™
and future revenue from the same; market acceptance of Teva’s
generic epinephrine auto-injector product and future revenue from
the same; our expectations regarding whether the FDA will pursue
withdrawal of approval for AMAG Pharmaceuticals Inc.’s Makena®
subcutaneous auto injector following the recent FDA advisory
committee meeting and future prescriptions, market acceptance and
revenue from Makena® subcutaneous auto injector; Teva’s ability to
successfully commercialize VIBEX® Sumatriptan Injection USP and the
amount of revenue from the same; continued growth of prescriptions
and sales of OTREXUP®; the timing and results of the Company’s or
its partners’ research projects or clinical trials of product
candidates in development including projects with Teva and Pfizer
and our proprietary programs for ATRS-1701 and our development
program for the use of subcutaneous methotrexate for the treatment
of ectopic pregnancy; actions by the FDA or other regulatory
agencies with respect to the Company’s products or product
candidates of its partners; continued growth in product,
development, licensing and royalty revenue; achievement of the 2019
revised revenue guidance; the Company’s ability to meet loan
extension and interest only payment milestones and the ability to
repay the debt obligation to Hercules Capital; successful
completion of the transaction with Ferring International Center,
S.A.; the Company’s ability to obtain financial and other resources
for its research, development, clinical, and commercial activities
and other statements regarding matters that are not historical
facts, and involve predictions. These statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results, performance, achievements or prospects to be
materially different from any future results, performance,
achievements or prospects expressed in or implied by such
forward-looking statements. In some cases you can identify
forward-looking statements by terminology such as ''may'',
''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'',
''anticipate'', ''believe'', ''estimate'', ''predict'',
''potential'', ''seem'', ''seek'', ''future'', ''continue'', or
''appear'' or the negative of these terms or similar expressions,
although not all forward-looking statements contain these
identifying words. Additional information concerning these and
other factors that may cause actual results to differ materially
from those anticipated in the forward-looking statements is
contained in the "Risk Factors" section of the Company's Annual
Report on Form 10-K, and in the Company's other periodic reports
and filings with the Securities and Exchange Commission. The
Company cautions investors not to place undue reliance on the
forward-looking statements contained in this press release. All
forward-looking statements are based on information currently
available to the Company on the date hereof, and the Company
undertakes no obligation to revise or update these forward-looking
statements to reflect events or circumstances after the date of
this press release, except as required by law.
Contact:Jack HowarthVice President, Corporate
Affairs609-359-3016jhowarth@antarespharma.com
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Aug 2024 to Sep 2024
Antares Pharma (NASDAQ:ATRS)
Historical Stock Chart
From Sep 2023 to Sep 2024